Fifth Lane Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Fifth Lane Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-20,000	Closed	-$1.18M	–	211
2023 Q4	$1.18M	Buy	+20,000	New	+$1.12M	1.38%	9

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fifth Lane Capital's MRTX Position: Q1 2024 in Review

Fifth Lane Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 20,000 shares — an estimated $1.18M sold.

Fifth Lane Capital first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $1.18M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Fifth Lane Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Fifth Lane Capital sold 20,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.18M.
Fifth Lane Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Fifth Lane Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $1.18M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Fifth Lane Capital's 13F filing for Q1 2024, filed 2 May 2024.